COVID-19: GSK head 'optimistic' about having vaccine by 2021; mentions 'real challenge'

Emma Walmsley, CEO of world’s largest vaccine producing firm reportedly said that Covid-19 Vaccine would be widely available by next year. Speaking at an online event with Confederation of British Industry, executive he of GlaxoSmithKline opined that she was “optimistic” that world would have a solution to coronavirus by next year. However, as reported by wired.gov.net, she stated that real challenge lied in getting it in volume that is required.

GSK is contributing juvants, efficacy boosters that play a vital role in many vaccines, in several development alliances for potential future vaccines. One of its most vanced project with French pharmaceutical company Sanofi, which is aiming to launch its vaccine in 2020.

'Does not compromise safety' 

Re: World Bank Seeks $12 Billion To Help Poor Nations Secure COVID-19 Vaccines

Re: COVID-19 Vaccine: 100 Million ditional Vaccines Doses Secured For Poorer Countries

In her dress, Walmsley she stressed that vaccine’s industry’s accelerated speed at producing vaccine did not affect its safety. Supporting her claim, she said that regardless of expediated process, trials were not smaller than usual and regulators and companies were taking steps in parallel that were previously done consecutively.

Re: Moderna's COVID-19 Vaccine Safe For Older ults, Extended Trials Reveal

Re: COVID-19 Vaccine: Serum Institute To Make ditional 100 Million 'safe & Effective' Doses

Meanwhile, new trials conducted by Moderna Inc. revealed that its COVID-19 vaccine appeared safe and worked well with older ults. findings of trials were published in  New England Journal of Medicine and revealed that vaccine produced virus neutralizing antibodies at levels similar to those seen in ults. Moderna is alrey testing 100 microgram dose of it’s vaccine in Phase 3, and positive results would make it US’ first vaccine.

latest research was conducted as an extension of company’s Phase I safety trials which were first conducted in individuals aged 18-55. For purpose, researchers tested two doses of Moderna’s vaccine - 25 micrograms and 100 micrograms - in 40 ults aged 56 to 70 and 71 and older.